0001213900-23-074164.txt : 20230906 0001213900-23-074164.hdr.sgml : 20230906 20230906091648 ACCESSION NUMBER: 0001213900-23-074164 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230905 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230906 DATE AS OF CHANGE: 20230906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unicycive Therapeutics, Inc. CENTRAL INDEX KEY: 0001766140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813638692 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40582 FILM NUMBER: 231237992 BUSINESS ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 650-384-0642 MAIL ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 8-K 1 ea184727-8k_unicycive.htm CURRENT REPORT
0001766140 false 0001766140 2023-09-05 2023-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 5, 2023

 

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

   001-40582   81-3638692
(State or other jurisdiction of   (Commission File Number)   (IRS Employer
incorporation or organization)       Identification No.)

 

4300 El Camino Real, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 351-4495

 

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class: 

   Trading Symbol(s)    Name of each exchange on which registered: 
Common Stock    UNCY   Nasdaq Capital Market 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On September 5, 2023, Unicycive Therapeutics, Inc. (the “Company”) appointed Sara Kenkare-Mitra as an independent director.

 

Sara Kenkare-Mitra, PhD is currently President and Head of Research and Development at Alector where she leads all aspects of the company’s R&D efforts in neurodegeneration, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Prior to joining Alector, Dr. Kenkare-Mitra held roles of increasing responsibility at Genentech over the course of 23 years serving most recently as Senior Vice President, Development Sciences in Genentech’s research and early development unit.  During her tenure at Genentech, she led a large, integrated global organization of approximately 650 employees, and played a key role in the filing of more than 100 Investigational New Drug (IND)/clinical trial applications around the world, and the approval of 11 medicines for diverse diseases, including cancers and neurological diseases. Her team also enabled the successful development and approval of over 15 companion diagnostics.

 

Item 8.01 Other Events.

 

On September 6, 2023, the Company issued a press release announcing that Dr. Kenkare-Mitra was appointed a director of the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1

   Press Release of Unicycive Therapeutics, Inc. dated September 6, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 6, 2023

 

 

 UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
    Shalabh Gupta
    Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea184727ex99-1_unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED SEPTEMBER 6, 2023

Exhibit 99.1

 

 

 

Unicycive Therapeutics Strengthens Board of Directors with Appointment of
Sara Kenkare-Mitra, PhD

 

- Appointment adds decades of drug development experience from a seasoned executive –

 

LOS ALTOS, California, September 6, 2023 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara’s leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth.

 

“We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadership experience will make an immediate impact here at Unicycive,” said Shalabh Gupta, MD, Chief Executive Officer. “Sara adds a broad skill set to our Board with leadership expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory. Importantly, she has played a key role in the filing of more than 100 investigational new drug (IND) and clinical trial applications and worked on 11 drug approvals in multiple diseases. Sara’s appointment comes at a crucial time for Unicycive as we advance oxylanthanum carbonate towards filing of a new drug application and prepare to file an IND for UNI-494.”

 

Dr. Kenkare-Mitra, added, “I am honored to join the Unicycive Board of Directors to help advance the company’s purpose-driven strategy to solve the most pressing unmet medical needs in renal diseases. I look forward to helping Unicycive with my expertise and experience in preclinical and clinical development and navigating the regulatory landscape as the organization advances their assets.”

 

Sara Kenkare-Mitra, PhD is currently President and Head of Research and Development at Alector where she leads all aspects of the company’s R&D efforts in neurodegeneration, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Prior to joining Alector, Dr. Kenkare-Mitra held roles of increasing responsibility at Genentech over the course of 23 years serving most recently as Senior Vice President, Development Sciences in Genentech’s research and early development unit. During her tenure at Genentech, she led a large, integrated global organization of approximately 650 employees, and played a key role in the filing of more than 100 Investigational New Drug (IND)/clinical trial applications around the world, and the approval of 11 medicines for diverse diseases, including cancers and neurological diseases. Her team also enabled the successful development and approval of over 15 companion diagnostics.

 

 

 

Dr. Kenkare-Mitra received her PhD in Pharmaceutical Chemistry from the University of California, San Francisco (UCSF), where she also stayed on as a Post-Doctoral Fellow in the school of medicine and also completed a Fellowship in Clinical Pharmacology before joining Genentech. Dr. Kenkare-Mitra also holds adjunct faculty positions in the Department of Bioengineering and Therapeutic Sciences at UCSF and at the University of the Pacific in Stockton. She is an elected member of the National Academy of Medicine (NAM) and elected fellow of Association for the Advancement of Science (AAAS). She has been widely recognized for her work and leadership in the industry with awards such as the American Association of Pharmaceutical Scientists’ Alice E. Till Advancement of Women in Pharmaceutical Sciences Recognition, Endpoints’ 20 Most Extraordinary Women in Biopharma, Fierce Pharma’s Fiercest Women in the Life Sciences, and the University of California, San Francisco’s Distinguished Alumnus of the Year. She has served as a board member of the Genentech foundation and the Association of Women in Science (AWIS).

 

About Unicycive Therapeutics

 

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com.

 

Forward-looking statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward- looking statement, whether as a result of new information, future events or otherwise.

 

Investor Contact:

 

ir@unicycive.com

(650) 900-5470

 

SOURCE: Unicycive Therapeutics, Inc.

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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uncy-20230905.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 uncy-20230905_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 uncy-20230905_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Sep. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 05, 2023
Entity File Number 001-40582
Entity Registrant Name Unicycive Therapeutics, Inc.
Entity Central Index Key 0001766140
Entity Tax Identification Number 81-3638692
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4300 El Camino Real
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Los Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94022
City Area Code 650
Local Phone Number 351-4495
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol UNCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea184727-8k_unicycive_htm.xml IDEA: XBRL DOCUMENT 0001766140 2023-09-05 2023-09-05 iso4217:USD shares iso4217:USD shares 0001766140 false 8-K 2023-09-05 Unicycive Therapeutics, Inc. DE 001-40582 81-3638692 4300 El Camino Real Suite 210 Los Alto CA 94022 650 351-4495 Common Stock UNCY NASDAQ false false false false true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !=*)E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 72B97[>W'].\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OIW^D8.CFLN))07!!\18FL[O!I@W)2+MO;UIWNX@^@,?,_/+- M-S M>HE#H.

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

J MQ"(6,P$ "(" / " 8<0 !X;"]W;W)K8F]O:RYX;6Q0 M2P$"% ,4 " 72B97)!Z;HJT #X 0 &@ @ 'G$0 M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 72B9799!Y MDAD! #/ P $P @ ',$@ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "0 ) #X" 6% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://unicycive.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea184727-8k_unicycive.htm ea184727ex99-1_unicycive.htm uncy-20230905.xsd uncy-20230905_lab.xml uncy-20230905_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea184727-8k_unicycive.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea184727-8k_unicycive.htm" ] }, "labelLink": { "local": [ "uncy-20230905_lab.xml" ] }, "presentationLink": { "local": [ "uncy-20230905_pre.xml" ] }, "schema": { "local": [ "uncy-20230905.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "UNCY", "nsuri": "http://unicycive.com/20230905", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea184727-8k_unicycive.htm", "contextRef": "AsOf2023-09-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://unicycive.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea184727-8k_unicycive.htm", "contextRef": "AsOf2023-09-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unicycive.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-074164-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-074164-xbrl.zip M4$L#!!0 ( !=*)E?2<_'#810 #EH 9 96$Q.#0W,CT]:W?:.-/?LWN2LP&,N220E.<0("E)VTT?I/Y;W=XZZKO0#_J:SH=4WW7M2C8[&HTRHWS& MXKULKEPN9\?8)^5WJHP3^\F2E,M^N?C45OML0-.ZZ;C45-ETD*&;3\OA8^NT MJ\(-/=85GX1(\MD%T-"JS09$.Y>R?F.LJYO8M>AW=<.NNF,5Y-S^*CK\'M,! MXV5]Z?)),<= 8&^!P=Q$T/(QU MNKVL?YWV\DQ=G:CZD&54:R"Z266IF!+6Q:@&GP3_.W)UUV#5HZS_":T#YE*" M0-+LNZ21=/JEH_.E!^3U(<;C M0\CC*P 5ZM-1;QE>E!X8Z!

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end